Titan pharmaceuticals steroids

Opiant Pharmaceuticals, Inc. ("we", "our" or the "Company"), a Delaware corporation, is a specialty pharmaceutical company that develops pharmacological treatments for substance use, addictive and eating disorders. We were incorporated in the State of Nevada in June 2005 as Madrona Ventures, Inc. and, in September 2009, we changed our name to Lightlake Therapeutics Inc. In January 2016, we again changed our name to Opiant Pharmaceuticals, Inc. Our fiscal year end is July 31. On October 2, 2017, we changed our state of incorporation from the State of Nevada to the State of Delaware pursuant to an Agreement and Plan of Merger, dated October 2, 2017 whereby we merged with and into our recently formed, wholly-owned Delaware subsidiary, Opiant Pharmaceuticals, Inc.  ... More ...  

We are a pharmaceutical company developing proprietary therapeutics for the treatment of serious medical disorders. Our product development programs utilize our proprietary long-term drug delivery platform, ProNeura(TM), and focus primarily on innovative treatments for select chronic diseases for which steady state delivery of a drug provides an efficacy and/or safety benefit. Probuphine®, our first product candidate based on the ProNeura platform, was approved by the United States Food and Drug Administration, or FDA, on May 26, 2016 for the maintenance treatment of opioid dependence in patients who are stable on low to moderate doses of daily sublingual buprenorphine treatment. We have licensed development and commercialization rights of Probuphine for the . and Canadian markets to Braeburn Pharmaceuticals, Inc.  ... More ...  

Titan pharmaceuticals steroids

titan pharmaceuticals steroids

Media:

titan pharmaceuticals steroidstitan pharmaceuticals steroidstitan pharmaceuticals steroidstitan pharmaceuticals steroidstitan pharmaceuticals steroids

http://buy-steroids.org